UAB is one of four institutions leading clinical trials evaluating the efficacy of adding pembrolizumab to the treatment of endometrial cancer.
Author: Hadley Turner
Media contact: Brianna Hoge
Charles A. Reese, III, MD
Photo: Steve WoodA new study published in the New England Journal of Medicine evaluated the efficacy of adding pembrolizumab to the current frontline standard of care for women with advanced primary or recurrent endometrial cancer.
The primary objective of this study was to evaluate the efficacy of adding pembrolizumab to chemotherapy as a treatment for women diagnosed with advanced primary or recurrent endometrial cancer. Pembrolizumab is a type of immunotherapy that stimulates the body’s immune system to fight cancer cells.
Participants who received pembrolizumab in addition to chemotherapy, particularly paclitaxel and carboplatin, the current frontline standard of care, showed significantly improved outcomes compared with women who received chemotherapy alone. Specifically, in patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard-of-care chemotherapy significantly prolonged progression-free survival compared to chemotherapy alone.
Charles A. Leath, III, MD, Chair of the Department of Gynecologic Oncology, University of Alabama at Birmingham, said: “This study has the potential to change the current management of women with advanced primary or recurrent endometrial cancer. is very high.”
Leath said the potential impact of this study is important because it could change the current management of women with advanced primary or recurrent endometrial cancer.
Click here to view other cancer clinical trials available at UAB.